Treatment analysis of Bilateral synchronous sporadic renal masses
Yuan Pingcheng1, Cheng Xiaogang1, Gui Dingwen1, Wang Liang2,
1Department of Urology, Huangshi Central Hospital,Huangshi,Hubei, 435000,China; 2Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abstract：Objective: To discuss the therapies of bilateral synchronous sporadic renal masses. Methods: The data of 26 bilateral synchronous sporadic renal masses were analyzed retrospectively. All the 26 patients underwent bilateral retroperitoneoscopic surgeries and were subjected to staged procedures. Bilateral nephron sparing surgery (NSS) was performed on 16 patients. NSS on one side and RN radical nephrectomy (RN) on other side were performed on 10 patients. The median follow-up time was 59 (18-85) months. Results: Pathological results showed that there were 20 cases of bilateral clear cell carcinoma, 1 case of bilateral papillary carcinoma, 2 cases of bilateral benign tumor, 1 case of right renal clear cell carcinoma and left renal cell carcinoma, and 1 case of left renal clear cell carcinoma and right kidney benign tumor. Nineteen patients survived without recurrence. Four survived with tumor recurrence and there were 3 deaths. The 3-year overall survival rate was 92.3%. The 3-year cancer special survival rate was 76.9%. Conclusions: The main subtype of bilateral synchronous sporadic renal masses was clear cell carcinoma. Staged NSS was the preferred choice for the management of bilateral synchronous sporadic renal masses. Targeted therapy combined with surgery is positive significance for bilateral synchronous sporadic renal masses.
[1]Lowrance WT, Yee DS, Maschino AC, et al. Developments in the surgical management of sporadic synchronous bilateral renal tumors. BJU Int, 2010,105(8):1093-1097. [2] Marshall FF, Stewart AK, Menck HR. The national cancer data base: a report on kidney cancers. Cancer, 1997,80(11):2167-2174 [3]Paola DC, Hein VP, Boudewijn VD, et al. Cytogenetic investigation of synchronous bilateral renal tumors. Cancer Gene Cytogenet, 1996,89(1):57-60. [4]Pahernik S, Roos F, Wiesner C, et al. Nephron sparing surgery for renal cell carcinoma in a solitary kidney. World J Urol, 2007,25(5):513-517. [5]Godley PA, Stinchcombe TE. Renal cell carcinoma. Curr Opin Oncol, 1999,11(3):213-217. [6]Hintzy MC, Hupertan V, Larousserie F, et al. Sporadic bilateral kidney tumour: practical approach and place of conservative surgery. Prog Urol, 2006,16(2):134-138. [7]Pahernik S, Cudovic D, Roos F, et al. Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. BJU Int, 2007,100(1):26-29. [8]Singer EA, Bratslavsky G. Management of locally recurrent kidney cancer. Curr Urol Rep, 2010,11(1):15-21 [9]Lerner SE, Hawkins CA, Blute ML, et al. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol, 1996,155(6):1868-1873. [10]Butler B, Novick AC, Miller DP, et al. Management of small unilateral renal cell carcinomas: radical versus nephron sparing surgery. Urology, 1995,45(1):34-40. [11]Blute ML, Amling CL, Bryant SC, et al. Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease. Mayo Clin Proc, 2000,75(10):1020-1026. [12]迟强,于满,王志勇,等.保留肾单位手术治疗双肾细胞癌十例临床分析.中华肿瘤防治杂志,2012,19(22):1745-1747. [13]Roos FC, Brenner W, Müller M, et al. Oncologic long-term outcome of elective nephron-sparing surgery versus radical nephrectomy in patients with renal cell carcinoma stage pt1b or greater in a matched-pair cohort. Urology, 2011,77(4):803-808. [14]魏东,张伟.肾癌多中心病灶和假包膜外肿瘤浸润的病理研究.中华泌尿外科杂志,2011,32(3):181-184. [15]Escudier B. Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther, 2011,11(6):825-836. [16]Rothman J, Crispen PL, Wong YN, et al. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology, 2008,72(1):138-142. [17]Patel N, Cranston D, Akhtar MZ, et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int, 2012,110(9):1270-1275. [18]Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 2012,118(4):997-1006. [19]Simmons MN, Brandina R, Hernandez AV, et al. Surgical management of bilateral synchronous kidney tumors: functional and oncological outcomes. J Urol, 2010,184(3):865-872.
